Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 5/20 | 0.43 |
| ▸ | ANPEP | P15144 | 4/20 | 0.43 |
| ▸ | ACP3 | P15309 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 4/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7718940 | 0.77 | LAP3 (0.38) | LAP3 | |
| SCHEMBL7742563 | 0.75 | LAP3 (0.64) | LAP3ANPEPACP3ERAP1ERAP2 | |
| Butane SCHEMBL7716702 | 0.73 | LAP3 (0.44) | LAP3ANPEPACP3CTSLCTSK | |
| SCHEMBL7718844 | 0.70 | METAP1 (0.31) | — | |
| SCHEMBL2224720 | 0.67 | LAP3 (0.55) | LAP3ANPEPACP3PIN1 | |
| SCHEMBL4107089 | 0.67 | LAP3 (0.55) | LAP3ANPEPACP3CTSCERAP1 | |
| SCHEMBL11500954 | 0.67 | CSNK1E (0.52) | LAP3ANPEPACP3 | |
| SCHEMBL22728397 | 0.67 | OPRM1 (0.44) | — | |
| SCHEMBL8169601 | 0.66 | CTSL (0.40) | CTSLCTSKCTSBCTSCCTSS | |
| SCHEMBL16057402 | 0.65 | LAP3 (0.47) | LAP3ANPEPACP3ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |